Observational studyJAMA network open2021

Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma.

Hedwig M Blommestein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.